Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$213 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
0.4 %
ROCE
-- %
P/E Ratio
0.1
P/B Ratio
2.2
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
1
Book Value
$--
EPS
$114.9
Face value
--
Shares outstanding
14,475,900
CFO
$-528.93 Mln
EBITDA
$-578.39 Mln
Net Profit
$-646.00 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Inhibrx Inc (INBX)
| -6.3 | 29.1 | -1.7 | -14.3 | 13.7 | -- | -- |
|
BSE Sensex
| 3.7 | -1.6 | 9.6 | 5.9 | 14.3 | 19.1 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Inhibrx Inc (INBX)
| -59.2 | 54.2 | -43.6 | 32.5 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Inhibrx Inc (INBX)
|
14.4 | 212.5 | 0.2 | 1,723.0 | 885,822.0 | 1262.7 | 0.1 | 2.2 |
| 50.7 | 8,079.8 | 1,208.8 | 131.7 | 13.4 | 6.3 | 62.1 | 3.9 | |
| 128.1 | 8,274.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 | |
| 151.1 | 7,421.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 53.2 | 10,499.6 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.3 | |
| 41.2 | 11,298.3 | 2,298.9 | 643.6 | 35.4 | 29.2 | 19.1 | 5.5 | |
| 54.2 | 6,635.5 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.3 | 13.9 | |
| 299.9 | 8,688.9 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23.4 | 14.6 | |
| 27.3 | 10,732.1 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.1 | |
| 124.2 | 12,288.6 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.4 | 4.9 |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate... targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037 Read more
Founder, Chairman, President & CEO
Mr. Mark Paul Lappe
Founder, Chairman, President & CEO
Mr. Mark Paul Lappe
Headquarters
La Jolla, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Inhibrx Inc (INBX) stood at $ 286 Mln as on 31-Mar-25
The share price of Inhibrx Inc (INBX) is $14.43 (NASDAQ) as of 13-Jun-2025 10:37 EDT. Inhibrx Inc (INBX) has given a return of 13.68% in the last 3 years.
Inhibrx Inc (INBX) has a market capitalisation of $ 213 Mln as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Inhibrx Inc (INBX) is 2.21 times as on 12-Jun-2025, a 15% discount to its peers’ median range of 2.59 times.
The P/E ratio of Inhibrx Inc (INBX) is 0.12 times as on 12-Jun-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Inhibrx Inc (INBX) and enter the required number of quantities and click on buy to purchase the shares of Inhibrx Inc (INBX).
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck squamous cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California. Address: 11025 North Torrey Pines Road, La Jolla, CA, United States, 92037
The CEO & director of Mr. Mark Paul Lappe. is Inhibrx Inc (INBX), and CFO & Sr. VP is Mr. Mark Paul Lappe.
There is no promoter pledging in Inhibrx Inc (INBX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,237
|
|
|
1,151
|
|
|
1,076
|
|
|
1,041
|
|
|
899
|
|
|
827
|
|
|
781
|
|
|
703
|
|
|
664
|
| Inhibrx Inc (INBX) | Ratios |
|---|---|
|
Return on equity(%)
|
1262.67
|
|
Operating margin(%)
|
885822
|
|
Net Margin(%)
|
861485.5
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Inhibrx Inc (INBX) was $0 Mln.
$0.10
(
